China Resources Pharmaceutical Group Limited
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese… Read more
China Resources Pharmaceutical Group Limited (640) - Total Liabilities
Latest total liabilities as of June 2025: €174.81 Billion EUR
Based on the latest financial reports, China Resources Pharmaceutical Group Limited (640) has total liabilities worth €174.81 Billion EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
China Resources Pharmaceutical Group Limited - Total Liabilities Trend (2016–2024)
This chart illustrates how China Resources Pharmaceutical Group Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
China Resources Pharmaceutical Group Limited Competitors by Total Liabilities
The table below lists competitors of China Resources Pharmaceutical Group Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Asian Star Anchor Chain Co Ltd Jiangsu
SHG:601890
|
China | CN¥1.61 Billion |
|
Retail Estates N.V.
LSE:0FSO
|
UK | €962.43 Million |
|
Granules India Limited
NSE:GRANULES
|
India | ₹29.61 Billion |
|
Jiangsu Baichuan HighTech New Materials Co Ltd
SHE:002455
|
China | CN¥10.20 Billion |
|
Luoniushan Co Ltd
SHE:000735
|
China | CN¥5.42 Billion |
|
Green Thumb Industries Inc
OTCQX:GTBIF
|
USA | $804.27 Million |
|
Xinyu Iron & Steel Co Ltd
SHG:600782
|
China | CN¥21.63 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down China Resources Pharmaceutical Group Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how China Resources Pharmaceutical Group Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for China Resources Pharmaceutical Group Limited (2016–2024)
The table below shows the annual total liabilities of China Resources Pharmaceutical Group Limited from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €159.67 Billion | +3.82% |
| 2023-12-31 | €153.80 Billion | +1.78% |
| 2022-12-31 | €151.10 Billion | -1.61% |
| 2021-12-31 | €153.58 Billion | +18.74% |
| 2020-12-31 | €129.34 Billion | +7.39% |
| 2019-12-31 | €120.44 Billion | +4.09% |
| 2018-12-31 | €115.72 Billion | +18.54% |
| 2017-12-31 | €97.62 Billion | +22.51% |
| 2016-12-31 | €79.68 Billion | -- |